U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861413) titled 'A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation' on Feb. 28.
Brief Summary: The purpose of this study is to evaluate the relative bioavailability of a VX-828 tablet formulation compared to a suspension and evaluate its safety and tolerability.
Study Start Date: March 04
Study Type: INTERVENTIONAL
Condition:
Cystic Fibrosis
Intervention:
DRUG: VX-828
Tablets for Oral Administration.
DRUG: VX-828
Suspension for Oral Administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vertex Pharmaceuticals Incorporated
Published by HT Digital Content Services with permission from Health D...